Back to search

National and Kapodistrian University of Athens

Structural studies of the oncoproteins c-Myc and PI3Kα and development of new synthetic molecules inhibiting their function

Abstract

dc:description

The MYC oncogene is at the crossroads of many important biological pathways and processes involved in neoplastic cell growth and proliferation. MYC is documented to be involved broadly in many cancers, in which its expression is estimated to be elevated or deregulated in up to 70% of human malignancies. Tumors with elevated MYC expression often exhibit highly proliferative, aggressive phenotypes. Despite our ever-growing understanding of MYC biology, currently no targeted therapeutic strategy is clinically available to treat tumors that have acquired elevated MYC expression. Detailed knowledge of protein structure is imperative for understanding mechanistic aspects of its function. However, intrinsically disordered proteins like c-Myc, under native conditions assume a wide range of structurally unrelated conformations, thus rendering the study of their structure quite challenging. Since no structure has been suggested for the c-Myc monomer so far, we tried to address the difficult task of proposing a possible set of structures for the c-Myc monomer through a series of advanced NMR experiments and CD spectroscopy, each of which provides a different type of structural information, most of which were utilized as restraints in structural calculations. Collectively, our experimental and computational data agree that the Leucine Zipper (LZ) of c-Myc is preconfigured prior to Max binding and may project the adjacent unfolded chain in the appropriate direction to achieve a “fly casting” interaction with Max. In contrast, the basic helix-loop-helix region is completely disordered, suggesting that it may not have a direct role in the initiation of hetero-dimerization. Remarkably, a stretch of about 23 amino acids in the LZ region is firmly pre-configured to an α-helix. Notably, that region of c-Myc was believed to interact with a 9-mer peptide derived from the LZ of Max that can impair the transcriptional activity of c-Myc in vivo. Using a combined experimental (NMR, CD) and Metadynamics approach, we tried to investigate in more detail the structural dynamics if these important peptides. Our findings suggest that the 23mer peptide retains the helical structure of the LZ but kinked in the middle. In contrast the 9mer peptide is completely disordered. Moreover the two peptides don’t interact, according to our NMR and CD measurements. A valuable approach to halt MYC protein on the path to cancer is to interrupt the interaction with its co-activator MAX. Since c-Myc monomer retains minimal pre-configure structure, we employed a combination of ligand-based drug design calculations based on knowledge of known inhibitors with the aim to discover new selective c-Myc/Max dimerization inhibitors. From the 34 candidate molecules that we tested through microscale thermophoresis (MST) and surface plasmon resonance (SPR), one had micromolar dissociation constant (Kd), quite close to the Kd of Max protein. That molecule is being undergoing currently cell viability measurements on a variety of cancer cell lines that over-express c-Myc, as well as evaluation of ADME-Tox properties and cancer therapeutic potential in mice bearing c-Myc induced tumors.Effective cancer therapy necessitates multi-level targeting of oncoproteins. Since there is a cross-talk between c-Myc/Max and PI3Kα mediated pathways, we also tried to design in silico PI3Kα inhibitors. First the conformational plasticity of the wild type and the oncogenic H1047R PI3Kα mutant in complex with PIK-108 inhibitor was studied through accelerated molecular dynamics simulations and free energy calculations. However, no significant differences were found between the two protein variants. Notwithstanding, representative conformations were utilized to screen in silico chemical libraries. This virtual exercise resulted in the discovery of two potent PI3Kα inhibitors, as suggested by both cell-based and cell-free binding assays.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Evangelidis, Thomas
  • Ευαγγελίδης, Θωμάς

Subjects

dc:subject × 14

Rights

dc:rights
Statement dc:rights
  • BY
Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/39819

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Evangelidis, Thomas; Ευαγγελίδης, Θωμάς. Structural studies of the oncoproteins c-Myc and PI3Kα and development of new synthetic molecules inhibiting their function. National and Kapodistrian University of Athens, 2017. http://hdl.handle.net/10442/hedi/39819